baber/WOPTO huggingface dataset:
Patent ES-2195798-T1 (ES)
Inventor: LEVINSON R SAUL
IPC: A23L33/15
Filed: 2000-08-28
Abstract: The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from symptoms associated with menopause, as well as prophylactic effects, and methods for using same.
Patent ES-2049199-T1 (ES)
Title: Conector modo de corriente.
Inventor: LEBARON JAMES BROWNLOW
IPC: H01R13/719
Filed: 1992-12-09
Abstract: UN ACOPLADOR EN MODO DE CORRIENTE PARA UN CABLE DE PAR RETORCIDO NO BLINDADO QUE INCLUYE UN HILO DE SEÑALES ELASTOMERICO Y UN MIEMBRO POSICIONADOR DE NUCLEO E CON NUCLEOS E AHUSADOS, DE PROTECCION CONTRA LOS TIRONES SOLIDARIOS PARA UN ACOPLAMIENTO MEJORADA A LOS HILOS, UN NUCLEO DE SEÑALES DE ESCRITURA DOS VECES MAYOR QUE EL NUCLEO DE SEÑALES DE LECTURA, UNA SUSPENSION PARA NUCLEOS METALICA, UN DISPOSITIVO DE MONTAJE POLARIZADO POR RESORTE SOBRECENTRADO, UNA CUBIERTA METALICA PARA MEJORAR EL BLINDAJE, UN RETEN ELASTICO QUE EVITA LA NECESIDAD DE TENER QUE PIVOTAR UN MIEMBRO DE ALOJAMIENTO SUPERIOR RESPECTO A LA UNIDAD DE BASE DURANTE EL MONTAJE Y BORDES Y ESQUINAS CONTORNEADOS PARA REDUCIR LA ACUMULACION DE CALOR.
Patent CY-1107226-T1 (CY)
Inventor: FRIEDL THOMAS
IPC: A61K31/4965
Filed: 2008-03-04
Abstract: A bilayer pharmaceutical tablet for the treatment of hypertension compring a first layer formulated for immediate release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix which contains telmisartan in substantially amorphous form, and a second layer formulated for immediate release of a thiazide diuretic from a fast disintegrating tablet matrix.
Patent CY-1111093-T1 (CY)
Inventor: PEASE ELIZABETH JANET
IPC: C07D403/12
Filed: 2010-08-26
Abstract: Pyrimidine derivatives of formula (I) wherein Q<SUB>1</SUB>, Q<SUB>2</SUB>, G and R<SUP>1 </SUP>are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
Patent CY-1111393-T1 (CY)
Inventor: GIULIANI GIAMMARIA
IPC: A61K6/00
Filed: 2011-04-15
Abstract: The present invention relates to preparations based on vegetal extracts of Ajuga reptans for favouring the growth of hair and stimulating the hair bulb. The preparations of the invention are in suitable formulations for oral administration or local application and are specifically suitable for the prevention and treatment of androgenic alopecia in males and females.
Patent CY-1112064-T1 (CY)
Inventor: ERKES BERND
IPC: C01B17/80
Filed: 2011-06-29
Abstract: In a method for continuous, complete or partial, catalytic oxidation of a starting gas containing sulfur dioxide (SO 2) and oxygen (O 2), the catalyst is kept active by carrying out the process in quasi-isothermal manner, with supply or abstraction of energy. An independent claim is included for apparatus for continuous, complete or partial, catalytic oxidation of a starting gas containing SO 2 and O 2, comprising at least one tubular contact apparatus, which is an upright heat exchanger consisting of at lesat one double-walled tube. The inner tube is a catalyst-filled reaction tube, around which heat is transferred by cooling medium. An absorber for separating sulfur trioxide is installed downstream of the contact apparatus.
Patent CY-1112703-T1 (CY)
Title: Υποκατεστημενες πιπεριδινο-διϋδρο-θειενο-πυριμιδινες
Inventor: POUZET PASCALE
IPC: C07D519/00
Filed: 2012-04-23
Abstract: Η εφεύρεση αφορά νέες πιπεριδινο-διυδρο-θειενο-πυριμιδίνες του τύπου (1), καθώς και φαρμακολογικά αποδεκτά άλατα αυτών, στον οποίο το Χ είναι SΟ ή SΟ2, κατά προτίμηση όμως SO, και στον οποίο τα R1, R2, R3 και R4 έχουν τις αναφερόμενες στην αξίωση 1 σημασίες, καθώς και φαρμακευτικές συνθέσεις, οι οποίες περιλαμβάνουν τις ενώσεις αυτές. Αυτές οι νέες πιπεριδινο-διυδρο-θειενο-πυριμιδίνες είναι κατάλληλες για τη θεραπεία συμπτωμάτων ή παθήσεων των αναπνευστικών οδών ή γαστρεντερικών συμπτωμάτων ή παθήσεων, φλεγμονωδών παθήσεων των αρθρώσεων, του δέρματος ή των οφθαλμών, παθήσεων του περιφερικού ή του κεντρικού νευρικού συστήματος ή καρκινικών παθήσεων.
Patent CY-1115753-T1 (CY)
Inventor: CHEVALLIER STÉPHANE
IPC: A61M5/32
Filed: 2014-09-05
Abstract: Syringe support and safety assembly consists of a supporting sleeve (16) for the body (20) of a syringe, and a safety component in the form of an inner sleeve (18) that can slide relative to the support sleeve between a retracted stand-by position and an active protection position when it projects beyond the supporting sleeve. The assembly further comprises a supple tip. The support and safety assembly consists of a supporting sleeve (16) for the body (20) of a syringe, and a safety component in the form of an inner sleeve (18) that can slide relative to the support sleeve between a retracted stand-by position and an active protection position when it projects beyond the supporting sleeve. The inner sleeve has a free end portion formed by a supple tip (40) with a thin end section (40A), joined to the rigid sleeve by adhesive, overmoulding, welding or a force fit. The assembly also incorporates a retaining system with flexible tongues (28, 30) and retaining surfaces (32, 34), actuated by the syringe plunger (12).
Patent CY-1115589-T1 (CY)
Inventor: BENCHERIF MAROUANE
IPC: A61K31/55
Filed: 2014-09-24
Abstract: A pharmaceutical composition comprising a pharmaceutically effective amount of at least two components, one of those components being a nicotinic agonist and one of those components being an acetylcholinesterase inhibitor, wherein the acetylcholinesterase inhibitor is donepezil.
Patent CY-1116561-T1 (CY)
Title: Αντισωματα anti-alpha2 ιντεγκρινης και oi χρησεις τους
Inventor: LAZARIDES ELIAS
IPC: C12N15/13
Filed: 2015-07-01
Abstract: Η εφεύρεση αναφέρεται σε αντισώματα αντι-α2 ιντεγκρίνης και στις χρήσεις τους. Περιγράφονται εξανθρωπισμένα αντισώματα, τα οποία προσδένονται στην I περιοχή της α2 ιντεγκρίνης και αναστέλλουν την αλληλεπίδραση της α2β1 ιντεγκρίνης με το κολλαγόνο. Περιγράφονται επίσης οι θεραπευτικές χρήσεις των αντισωμάτων αντι-α2 ιντεγκρίνης στην αντιμετώπιση των διαμεσολαβούμενων από την α2β1 διαταραχών, συμπεριλαμβανομένων των αντισωμάτων αντι-α2 ιντεγκρίνης που προσδένονται στην α2 ιντεγκρίνη χωρίς να ενεργοποιούνται τα αιμοπετάλια.
Patent CY-1117590-T1 (CY)
Title: Μεθοδος για βιομηχανικη κατασκευη βιολογικων καυσιμων
Inventor: BAYARRI FERRER NATIVIDAD
IPC: C11C3/06
Filed: 2016-06-01
Abstract: Η παρούσα εφεύρεση αφορά σε μια μέθοδο ταυτόχρονης λήψης διαφόρων συνθέσεων που περιλαμβάνουν αλκυλεστέρες λιπαρού οξέος (βιοντίζελ), φορμάλη γλυκερόλης και εστέρες φορμόλης γλυκερόλης λιπαρού οξέος.
Patent CY-1120250-T1 (CY)
Title: Ετεροκυκλικες αρωματικες ενωσεις χρησιμες ως εκκριταγωγα αυξητικης ορμονης
Inventor: YU GUIXUE
IPC: C07D513/04
Filed: 2017-11-15
Abstract: Καινοφανείς ετεροκυκλικές αρωματικές ενώσεις παρέχονται που είναι χρήσιμες σε διέγερση ενδογενούς παραγωγής ή αποδέσμευσης αυξητικής ορμόνης, οι εν λόγω ενώσεις έχοντας την γενική δομή του χημικού τύπου (I) όπου τα R1, R1', R2, R3, R4, Xa, Υ, Ζ, και n περιγράφονται ως εις το παρόν. Οι ενώσεις που παρέχονται εις το παρόν είναι χρήσιμες σε αγωγή παχυσαρκίας, οστεοπόρωσης (βελτίωση της πυκνότητας των οστών) και σε βελτίωση μάζας μυών και ισχύος μυών.
Patent CY-1120492-T1 (CY)
Title: Μια μορφοποιηση φαρμακου καθυστερημενης εκλυσης
Inventor: BRAVO GONZÀLES ROBERTO CARLOS
IPC: A61K47/36
Filed: 2018-08-06
Abstract: Καθυστερημένη έκλυση ενός φαρμάκου στο κόλον επιτυγχάνεται από μια μορφοποίηση καθυστερημένης έκλυσης που περιλαμβάνει έναν πυρήνα και μια επικάλυψη για τον πυρήνα. Ο πυρήνας περιλαμβάνει ένα φάρμακο και η επικάλυψη περιλαμβάνει μια εσωτερική στοιβάδα και μια εξωτερική στοιβάδα. Η εξωτερική στοιβάδα περιλαμβάνει ένα μείγμα από ένα πρώτο πολυμερές υλικό, το οποίο είναι ευαίσθητο σε επίθεση από βακτήρια του κόλου, και ένα δεύτερο πολυμερές υλικό, το οποίο έχει όριο pΗ περίπου 6 ή μεγαλύτερο. Η εσωτερική στοιβάδα περιλαμβάνει ένα μη ιονικό πολυμερές ως ένα τρίτο πολυμερές υλικό, το οποίο είναι διαλυτό στο εντερικό υγρό ή στο γαστρεντερικό υγρό, και έναν τουλάχιστον ρυθμιστικό παράγοντα και μια βάση. Πλεονεκτήματα των μορφοποιήσεων σύμφωνα με την παρούσα εφεύρεση περιλαμβάνουν επιταχυνόμενη έκλυση του φαρμάκου όταν εκτείθεται σε συνθήκες του κόλου και μείωση ή εξάλειψη μιας επίδρασης διατροφής ή/και αλκοόλης στην έκλυση του φαρμάκου μετά από τη χορήγηση.
Patent CY-1120937-T1 (CY)
Title: Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
Inventor: LÁZÁR JÓZSEF
IPC: A61K39/395
Filed: 2018-11-19
Abstract: Παρέχονται βελτιωμένες σταθερές στην αποθήκευση υγρές φαρμακευτικές μορφοποιήσεις αντισώματος. Συγκεκριμένα, περιγράφονται υγρές υδατικές φαρμακευτικές μορφοποιήσεις Αδαλιμουμάμπης που βασίζονται σε εναλλακτικά συστήματα ρυθμιστικού διαλύματος σε κιτρικό/φωσφορικό άλας και φαρμακευτικοί περιέκτες όπως συσκευές αυτόματης έγχυσης που τις περιέχουν.
Patent CY-1122419-T1 (CY)
Title: Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl
Inventor: MACDONALD LYNN
IPC: A01K67/027
Filed: 2019-12-10
Abstract: Παρέχονται ζώα πλην του ανθρώπου, μη ανθρώπινοι ιστοί, κύτταρα και γενετικό υλικό που περιλαμβάνουν μια τροποποίηση μιας ενδογενούς μη ανθρώπινης αλληλουχίας βαριάς αλυσίδας της ανοσοσφαιρίνης και που περιλαμβάνουν δράση ADAM6 που είναι λειτουργική σε ένα τρωκτικό (π.χ. έναν ποντικό), όπου τα ζώα πλην του ανθρώπου αναδιατάσσουν ανθρώπινα γονιδιακά τμήματα ελαφριάς αλυσίδας της ανοσοσφαιρίνης στο πλαίσιο σταθερών περιοχών βαριάς αλυσίδας και εκφράζουν μόρια ομοιάζοντα με ανοσοσφαιρίνη που περιλαμβάνουν ανθρώπινους μεταβλητούς τομείς ελαφριάς αλυσίδας της ανοσοσφαιρίνης συντετηγμένους με σταθερούς τομείς βαριάς αλυσίδας που είναι συγγενείς με ανθρώπινους μεταβλητούς τομείς ελαφριάς αλυσίδας της ανοσοσφαιρίνης συντετηγμένους με σταθερούς τομείς ελαφριάς αλυσίδας.
Patent CY-1123802-T1 (CY)
Title: Καθαρισμος πρωτεϊνων
Inventor: ROSE MICHAEL HARRY
IPC: C07K1/16
Filed: 2020-10-22
Abstract: Η παρούσα εφεύρεση αφορά μια μέθοδο για τον καθαρισμό πρωτεΐνης που περιλαμβάνει ένα στάδιο ημι-συνεχούς χρωματογραφίας όπου η συνεχής ροή συλλέγεται και φορτώνεται εκ νέου στη χρωματογραφική μήτρα.
Patent CY-1124827-T1 (CY)
Title: Αρωματικες συνθεσεις σωματος
Inventor: SHAVIT SHOVAL
IPC: A61Q13/00
Filed: 2021-11-11
Abstract: Παρέχεται ένα σύμπλοκο απελευθέρωσης αρώματος με ικανότητα παρατεταμένης συγκράτησης αρώματος που συμπεριλαμβάνει ένα ακρυλικό πολυμερές που εφαρμόζεται σε μία επιφάνεια ανθρώπινου σώματος. Το σύμπλοκο απελευθέρωσης αρώματος μπορεί να εφαρμόζεται με τη χρήση ενός κιτ που περιλαμβάνει μέσα για την εφαρμογή του συμπλόκου απελευθέρωσης αρώματος στην επιφάνεια του σώματος.
Patent GR-900300074-T1 (GR)
Title: Shaving unit incorporating a shaving aid
Inventor: AMRAM JAK IKITELLI KOYU
IPC: B26B21/44
Filed: 1991-07-31
Abstract: A Disposable shaving unit having one or more razor blades (4) that creates a smooth surface on the skin as a result of friction and contact with water without using other shaving aid materials wherein the production of an entire platform (5) and cap section (7) uses an injection process which defines a skin engaging surface composed of a blend of water insoluble polymer in an amount of 50-90% by weight that is polystyrene, thermoplastic rubber (with or withour filler) with or without polystyrene, polyethylene, polypropylene and polyacetal, water soluble polymer in an amount of 9-40% by weight and polyethylene glycol in an amount of 1-10 % by weight.
Patent GR-960300030-T1 (GR)
Title: Apparatus for the extraction of peat
Inventor: HAMERLINSKI WACLAW
IPC: C10G1/04
Filed: 1996-05-31
Abstract: An apparatus for the extraction of peat comprising an outer tank (1) and an inner tank compartment (3) having perforated walls (4,23) and being the actual container for peat to be extracted. Feeding pipes (13) for the supply of extracting medium extend into the inner tank compartment (3) while at least one outflow opening (7-11) is connected to the outer tank (1). Between the inner tank compartment (3) and the outer tank (1), there is a free space (38) filled with extracting medium. Preferably, the medium is supplied to a plurality of orifices within the inner tank compartment (3), and particularly to at least two different levels.
Patent HR-P20110374-T1 (HR)
Title: Use of an anti-cd151 antibody in the treatment of primary cancer
Inventor: HAEUW JEAN-FRAN OIS
IPC: C07K16/28
Filed: 2011-05-19
Abstract: Use of an antibody, or one of its functional fragments capable of binding to cluster of differentiation (CD)-151 protein and inhibiting the tumor growth for the preparation of a medicament for the treatment of cancer, is claimed. An independent claim is included for a composition for treating cancer, comprising the anti-CD151 antibody as active ingredient, which binds to the protein CD151 and/or to inhibit its metastasis promoting activity. ACTIVITY : Cytostatic. MECHANISM OF ACTION : CD151 protein binder.
Patent HR-P20110621-T1 (HR)
Inventor: CHENG HENGMIAO
IPC: C07D471/04
Filed: 2011-08-24
Abstract: Spoj Formule (I) ili njegova sol, naznačen time što: R1 je H ili (C1 do C8) alkil, izborno supstituiran s najmanje jednom skupinom R5;A je 3- do 10-eročlana cikloalkilna skupina; R2 je (C1 do C8) alkil, supstituiran s najmanje jednom skupinom R6, (C3 do C10) cikloalkil, (C2 do C8) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -NR7aR7b ili -N=CR8aR8b, gdje je svaki od navedenih (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C8 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;R3 je (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, halogen, cijano, -(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), COR12, (C8 do C14) aril ili (C2 do C9) heteroaril, gdje su navedeni (C1 do C6) alkil, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C2 do C8) alkenil, (C2 do C8) alkinil, (C8 do C14) aril i (C2 do C9) heteroaril izborno supstituirani s najmanje jednom skupinom R9;svaki R4 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C8) alkil, (C1 do C6) alkenil, (C1 do C8) alkinil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C9) heteroaril, -C(O)R12-C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkenila, (C1 do C6) alkinila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki R5 je neovisno -OH, halogen, CF3, -NR11aR11b, (C1 do C6) alkil, (C1 do C6) alkoksi, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C6 do C14) aril, (C2 do C9) heteroaril, -S(O)mR12, -S(O)mR11aR11b, -C(O)R12 ili -C(O)NR11aR11b, gdje je svaki od navedenih (C1 do C6) alkila, (C1 do C6) alkoksi, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C14) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R9;svaki R6 je neovisno -OH, (C1 do C6) alkinil, cijano, (C3 do C10) cikloalkil, (C2 do C9) cikloheteroalkil, (C8 do C14) aril, (C2 do C8) heteroaril, -C(O)R12 -C(O)NR11aR11b, -S(O)mR12, -S(O)mNR11aR11b, -NR11aS(O)mR12-(CH2)nC(O)OR10, -(CH2)nC(O)N(R11aR11b), -OC(O)R12, -NR11aC(O)R12 ili -NR11aC(O)N(R11aR11b), gdje je svaki od navedenih (C1 do C6) alkinila, (C3 do C10) cikloalkila, (C2 do C9) cikloheteroalkila, (C6 do C12) arila, te (C2 do C9) heteroarila izborno supstituiran s najmanje jednom skupinom R13;svaki od R7a i R7b je neovisno H, (C1 do C8) alkil, (C2 do C6)alkenil, (C2 do C6)alkinil, (C3 do C10) cikloalkil ili (C6 do C10)aril, gdje je svaki od navedenih (C1 do C6) alkila, (C2 do C6)alkenila, (C2 do C6)alkinila, (C3 do C10) cikloalkila, te (C6 do C10)arila izborno supstituiran s najmanje jednom skupinom R9; ili se R7a i R7b može uzeti zajedno s atomom dušika kako bi tvorili
Patent SI-1676924-T1 (SI)
Title: Cyclic GMP dependent protein kinase of toxoplasma gondii as a chemotherapeutic target for antiprotozoal agents
Inventor: GURNETT ANNE
IPC: C12P21/00
Filed: 2000-04-10
Abstract: A protozoal cyclic GMP dependent protein kinase has been isolated and cloned from Toxoplasma gondii. This enzyme may be used in screening assays to identify potential antiprotozoal agents.
Patent SI-1248776-T1 (SI)
Title: Semi-synthetic taxanes with antitumor and antiangiogenetic activities
Inventor: BOMBARDELLI EZIO
IPC: A61P35/00
Filed: 2001-01-15
Abstract: Seco-baccatin III derivatives of formula: wherein R, R<SUB>1</SUB>-R<SUB>4</SUB>, <?delete-start id="DEL-S-00001" date="20070710" ?>R<SUP>1</SUP><?delete-end id="DEL-S-00001" ?> <?insert-start id="INS-S-00001" date="20070710" ?>R'<?insert-end id="INS-S-00001" ?>, <?delete-start id="DEL-S-00002" date="20070710" ?>R<SUP>11</SUP><?delete-end id="DEL-S-00002" ?> <?insert-start id="INS-S-00002" date="20070710" ?>R''<?insert-end id="INS-S-00002" ?>, and <?delete-start id="DEL-S-00003" date="20070710" ?>R<SUP>111</SUP><?delete-end id="DEL-S-00003" ?> <?insert-start id="INS-S-00003" date="20070710" ?>R'''<?insert-end id="INS-S-00003" ?> are disclosed herein; pharmaceutical compositions comprising seco-baccatin III derivative; and methods for treating cancer, arthritis, and inhibiting angiogenesis in an animal comprising administrating to a patient in need thereof a therapeutically effective amount of a seco-baccatin III derivative are disclosed.
Patent SI-1467993-T1 (SI)
Title: Method for producing scopine esters
Inventor: BRANDENBURG JORG
IPC: C07D451/10
Filed: 2002-12-24
Abstract: Preparation of quaternized scopine 2,2-di-(hetero)arylalkanoic acid esters (I) involves single-stage reaction of a quaternized scopine compound (II) with a di-(hetero)aryl-alkanoic acid (or activated ester) derivative (III). Preparation of quaternized scopine esters of formula (I) involves single-stage reaction of a quaternized scopine compound of formula (II) with a diaryl-alkanoic acid derivative of formula RC(O)C(Ar) 2R 1> (III). [Image] X, Y : Cl, Br, I, MeSO 3 or CF 3SO 3; R 1>OH, 1-4C alkyl, 1-4C alkoxy, CF 3 or F; Ar : phenyl, naphthyl, thienyl or furyl (all optionally substituted by 1-2 1-4C alkyl, 1-4C alkoxy, OH, F, Cl, Br or CF 3); and R : OH, OMe, OEt, O-N-succinimidyl, O-N-phthalimidyl, nitrophenoxy, fluorophenoxy, pentafluorophenoxy, vinyloxy, 2-allyloxy, SMe, SEt or SPh. An independent claim is also included for the use of (II) as starting materials for the production of (I). ACTIVITY : Antiasthmatic; Antiinflammatory. MECHANISM OF ACTION : Anticholinergic.
Patent SI-1501993-T1 (SI)
Title: Assembly comprising a door leaf and hinges, and a shower stall
Inventor: KIEFER ZOLTAN ANTON
IPC: A61H33/00
Filed: 2003-04-25
Abstract: The invention relates to an assembly comprising a door leaf (1), which has at least two undercut blind holes (26), and comprising at least two hinges (3) each consisting of a door-side and a wall-side hinge part (4,5). In order to fasten the door-side and/or wall-side hinge part, expanding plugs (20) are provided that have a distal expanding element (22) as well as a retaining and stop element (23). In addition, an expanding/fastening element (21) is provided that serves to expand the expanding elements and to fasten the hinge to the expanding plug. The expanding/fastening element can comprise a screw bolt (26) and a nut (28) or a mounting part (30) with a hole for accommodating a screw (31), with which the mounting part is screwed to the expanding plug. The invention also relates to a shower stall having one or more lateral walls and one or more assemblies of the aforementioned type.
Patent SI-1516720-T1 (SI)
Title: Composite element comprising a polyurethane adhesion promoter
Inventor: CALGUA ERWIN
IPC: E04C1/40
Filed: 2004-08-07
Abstract: Laminate (IA) comprises (i) a first covering layer, (ii) an adhesion promoter layer containing polyurethane with a density of 400-1200 g/l, (iii) a foam layer containing polyisocyanurate with a density of 20-300 g/l, (iv) optionally a second adhesion promoter layer containing polyurethane with a density of 400-1200 g/l and thickness of 50-500 mu m and (v) a second covering layer. Independent claims are also included for the following: (1) production of laminate (IB) comprising (i) a first covering layer, (ii) a reactive adhesion promoter layer containing polyurethane with a density of 400-1200 g/l, (iii) a foam layer containing polyisocyanurate with a density of 30-100 g/l, (iv) optionally a second adhesion promoter layer containing polyurethane with a density of 400-1200 g/l and (v) a second covering layer; (2) use of a polyurethane adhesion promoter to improve the adhesion between layers of a laminate containing a polyisocyanurate foam and covering layers.
Patent SI-1623094-T1 (SI)
Title: Controlled expansion of rock bolt
Inventor: PERSSON TOMMY
IPC: E21D21/00
Filed: 2004-05-12
Abstract: The present invention is related to a method for manual installation of rock bolts expandable by means of a pressure media comprising manual coupling of a pressure source to a rock bolt to be expanded. The method comprises the steps of an operator starting a sequence whereby the rock bolt is pressurized to a predetermined pressure, and it being ensured that the predetermined pressure is kept for a predetermined period of time. The present invention is also related to such a control system, and an apparatus comprising such a control system.
Patent SI-1559513-T1 (SI)
Title: Pressing tool with pivotable jaws
Inventor: BIRK MICHAEL
IPC: B25B27/10
Filed: 2005-01-21
Abstract: The pressing tool has a pressing fork head (1) with two opposite turning pressing jaws (2), having at least one tilting hinge (3) to create a tilting angle (4) between the jaws of 120[deg]-30[deg]. The tilting hinge includes at least one locking element enabling a preset tilting angle to be fixed. The locking element has at least one spring element and one moving bolt.
Patent SI-2292733-T1 (SI)
Title: Production from blood of cells of neural lineage
Inventor: FULGA VALENTIN
IPC: C12N5/00
Filed: 2005-12-14
Abstract: A composition of matter is provided, wherein the composition of matter is derived from one or more sources selected from the group consisting of: a hematopoietic source and blood. The composition of matter comprises a population of at least 5 million cells which have a density of less than 1.072 g/ml, and at least 1% of which are CD34+CD45-/dim, wherein the population has a CD43+CD45-/dim enrichment factor of greater than or equal to 1.6 over the one or more sources. Other embodiments are also described.
Patent SI-2037785-T1 (SI)
Title: Hand mixer comprising a safety lock system
Inventor: GOLAVSEK SAMO
IPC: A47J43/00
Filed: 2007-06-13
Abstract: A hand mixer (1) comprises a housing, a motor, a motor switch (4) with an OFF position, a pulse ON position and at least one permanent ON position, at least one first coupling device for coupling an attachment thereto in order to drive it in the permanent ON position, a second coupling device for coupling an attachment thereto in order to drive it in the pulse ON position, a coupling opening that is equipped with a closure (8) in such a manner that the second coupling device is only accessible for coupling an attachment thereto when the closure (8) is opened, and a locking element (14) that is mechanically connected to the closure (8), and interacts with a counter-locking element (16) of the motor switch (4) in such a manner that the closure (8) cannot be opened when the motor switch (4) is in the permanent ON position. According to the invention, the locking element (14) is connected to the closure (8) via at least one hinged connecting element (11, 12). The invention allows the construction of a hand mixer (1) to be simplified, the second coupling device for coupling a blender rod being inaccessible for safety reasons when the motor switch (4) is in its permanent ON position.